Company news

Voyager Therapeutics, Inc. news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Voyager Technologies, Inc. Completes $402.5 Million Convertible Senior Notes Offering

September 28, 2026

Voyager Technologies, Inc. Announces Proposed Convertible Senior Notes Offering

September 22, 2026

Voyager Demonstrates Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 6-Month GLP Toxicology Study; Initiation of Clinical Trial in Alzheimer’s Disease Expected H2 2026

July 13, 2026

Voyager’s Tau-Targeted Gene Therapy VY1706 for Alzheimer’s Disease to Be Featured in Developing Topics Poster Presentation at AAIC 2026

June 29, 2026

Voyager to Present at H.C. Wainwright 7th Annual Neuro Perspectives Hybrid Conference

June 10, 2026

Voyager Receives FDA IND Clearance for VY1706, First Gene Therapy Approach to Reducing Tau Production in the Brain for Alzheimer’s Disease

June 1, 2026

Voyager ASGCT Late Breaker: Single IV Dose of VY1706 Well Tolerated, Reduced Tau in 3-Month GLP Toxicology Data; Clinical Trial in Alzheimer’s Disease Expected H2 2026

May 13, 2026

Voyager Reports First Quarter 2026 Financial and Operating Results

May 7, 2026

Voyager IV-Delivered CNS Gene Therapies Featured in Multiple Presentations at ASGCT 2026, Including Late Breaker on Tau-Targeted VY1706 for Alzheimer’s Disease

April 27, 2026

Voyager Reports Fourth Quarter and Full Year 2025 Financial and Operating Results

March 8, 2026

Voyager to Present at Upcoming Investor Conferences

February 9, 2026

Voyager Reports Third Quarter 2025 Financial and Operating Results

November 10, 2025

Transition Bio and Voyager Announce Collaboration to Advance Small Molecules Targeting TDP-43 in ALS and Frontotemporal Dementia

November 10, 2025

Voyager Reports Second Quarter 2025 Financial and Operating Results

August 6, 2025

Voyager Adds Fourth Wholly-Owned Alzheimer’s Disease Program to Pipeline, Complementing Existing Tau and Amyloid Assets with New APOE Approach

July 16, 2025

Voyager to Present at H.C. Wainwright 6th Annual Neuro Perspectives Hybrid Conference

June 10, 2025

Voyager Demonstrates ALPL Receptor-Mediated Blood-Brain Barrier Transport of Novel AAV Capsids in Molecular Therapy Publication

May 15, 2025

Voyager Reports First Quarter 2025 Financial and Operating Results

May 6, 2025

Voyager Next-Generation CNS Capsids Featured at ASGCT 28th Annual Meeting

April 28, 2025

Voyager Presents Robust Preclinical Data from Tau Targeting Gene Therapy and Antibody Programs at AD/PD™ 2025

March 31, 2025

Voyager Reports Fourth Quarter and Full Year 2024 Financial and Operating Results

March 11, 2025

Voyager Therapeutics Announces Fourth Quarter 2024 Conference Call and Webcast

March 4, 2025

Voyager Reports Positive Topline Data for Single Ascending Dose (SAD) Trial of Anti-Tau Antibody VY7523 and Initiates Multiple Ascending Dose (MAD) Trial in Alzheimer’s Disease

March 3, 2025

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

February 25, 2025

Voyager Provides Update on SOD1 ALS Gene Therapy Program

February 10, 2025

Voyager Selects Tau Silencing Gene Therapy Development Candidate for Alzheimer’s Disease

November 19, 2024

Voyager Reports Third Quarter 2024 Financial and Operating Results

November 11, 2024

Voyager Therapeutics Announces Third Quarter 2024 Conference Call and Webcast

November 4, 2024

Voyager Advances Collaboration with Neurocrine; Third Gene Therapy Development Candidate Selected

September 15, 2024

Voyager Enters into License for Next-Generation Capsid, Bringing Partnered Portfolio of TRACER-Enabled Gene Therapies to 14

September 4, 2024

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

August 28, 2024

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

August 5, 2024

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

July 29, 2024

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

June 12, 2024

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

May 15, 2024

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

May 12, 2024

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

May 7, 2024

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

May 5, 2024

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

April 15, 2024

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

March 12, 2024

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

February 27, 2024

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

February 25, 2024

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

February 20, 2024

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

February 19, 2024

Voyager Therapeutics Announces Proposed Public Offering

January 3, 2024

Voyager Therapeutics Announces Pricing of Public Offering

January 3, 2024

Voyager Therapeutics Enters Capsid License Agreement and Strategic Collaboration with Novartis to Advance Novel Gene Therapies

January 1, 2024

Voyager Therapeutics Announces Selection of Development Candidate for SOD1 Amyotrophic Lateral Sclerosis Gene Therapy Program

December 5, 2023

Voyager Therapeutics Reports Third Quarter 2023 Financial and Operating Results

November 5, 2023

Voyager Therapeutics Announces Third Quarter 2023 Conference Call and Webcast

October 29, 2023

Older news releases →

Calls

The 5 newest of 16 calls. Every call is listed under its year.

Decks

The 5 newest of 9 decks. Every deck is listed under its year.